公开(公告)号：US10456461B2

公开(公告)日：2019-10-29

申请号：US16025624

申请日：2018-07-02

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  The Government of the United States, as Represented by The Secretary of The Army

发明人： Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney

IPC分类号： A61K39/12 ,  C12Q1/6888 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

摘要： The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

公开(公告)号：US20200030435A1

公开(公告)日：2020-01-30

申请号：US16596175

申请日：2019-10-08

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  The Government of the United States, as Represented by The Secretary of The Army

发明人： Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney

IPC分类号： A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12Q1/6888

摘要： The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

公开(公告)号：US20180369358A1

公开(公告)日：2018-12-27

申请号：US16025624

申请日：2018-07-02

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  The Government of the United States, as Represented by The Secretary of the Army

发明人： Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney

IPC分类号： A61K39/12 ,  C12Q1/6888 ,  C12N7/00 ,  C07K14/005 ,  C12N15/86 ,  A61K39/00

CPC分类号： A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24143 ,  C12N2770/24162 ,  C12Q1/6888 ,  Y02A50/386 ,  Y02A50/394

摘要： The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.

公开(公告)号：US20210069317A1

公开(公告)日：2021-03-11

申请号：US16952864

申请日：2020-11-19

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  The Government of the United States, as Represented by The Secretary of The Army

发明人： Alexander G. Pletnev ,  Joseph R. Putnak ,  Robert M. Chanock ,  Brian R. Murphy ,  Stephen S. Whitehead ,  Joseph E. Blaney

IPC分类号： A61K39/12 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12Q1/6888

摘要： The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,

公开(公告)号：US20190194260A1

公开(公告)日：2019-06-27

申请号：US16083652

申请日：2017-03-11

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services ,  The Johns Hopkins University

发明人： Stephen S. Whitehead ,  Sara E. Woodson ,  Anna P. Durbin ,  Alexander G. Pletnev ,  Konstantin A. Tsetsarkin

IPC分类号： C07K14/005 ,  A61K39/12

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  C12N2770/24122 ,  C12N2770/24134 ,  C12N2770/24144 ,  C12N2770/24162 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/392 ,  Y02A50/394 ,  Y02A50/396

摘要： The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flaviviruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3′ untranslated region from a second flavivirus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype 1, a second attenuated virus that is immunogenic against dengue serotype 2, a third attenuated virus that is immunogenic against dengue serotype 3, and a fourth attenuated virus that is immunogenic against dengue serotype 4. The present disclosure further relates to methods of inducing immune responses, as well as preventing or treating ZIKV infections, and in certain embodiments, the combined prevention or treatment of ZIKV and another flavivirus, e.g., dengue virus.